Metabolomics for biomedical research:
Gespeichert in:
Weitere Verfasser: | |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
London, United Kingdom ; San Diego, CA, United States ; Cambridge, MA, United States ; Kidlington, Oxford, United Kingdom
Academic Press, an imprint of Elsevier
2020
|
Schlagworte: | |
Online-Zugang: | TUM01 |
Beschreibung: | Intro -- Metabolomics for Biomedical Research -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Introduction to metabolomics -- 1. What is metabolomics? -- 2. Flow chart of metabolomic research -- 2.1. Scientific question -- 2.2. Study design: General aspects -- 2.3. Study design: Pilot study and power calculation -- 2.4. Study design: Sample identity -- 2.5. Study design: Preanalytics -- 2.6. Study design: Sample matrix -- 2.7. Study design: Confounders -- 2.8. Study design: Time schedule -- 2.9. Study design: Randomization -- 2.10. Study design: Budgeting and resources 2.11. Study design: Contingency plan -- 2.12. Study design: Legal aspects -- 2.13. Study design: Governance -- 2.14. Study design: Replication -- 2.15. Analytics -- 2.16. Data validation -- 2.17. Data release -- 3. Future trends -- 3.1. Standardization -- 3.2. Coverage and speed -- 3.3. Accessibility -- 3.4. Mechanisms of disease -- 3.5. Biomarkers -- Acknowledgments -- References -- Chapter 2: Confounders in metabolomics -- 1. Introduction to the confounder concept -- 2. Important confounders in metabolomics -- 2.1. Genetic background and ethnicity -- 2.2. Sex -- 2.3. Age -- 2.4. Nutrition 3. Body mass index -- 3.1. Physical activity -- 3.2. Alcohol -- 3.3. Smoking -- 3.4. Stress -- 3.5. Circadian rhythm -- 3.6. Hormonal status -- 3.7. Medication -- 3.8. Lifestyle -- 4. Disease -- 5. Consequences for study design -- 6. Future trends -- References -- Chapter 3: Pre-analytics in biomedical metabolomics -- 1. Introduction -- 2. Principles to be considered before the collection of body fluids for biomedical metabolomics -- 2.1. Patients instructions and sophisticated questionaries can avoid outliers -- Points to be considered before sample collection Suggestions of choice for additional points in a study questionnaire -- 2.1.1. Control groups: Undiagnosed, asymptomatic diseases of apparently healthy subjects can bias metabolomics findings -- 2.2. Sample collectors for blood and urine in biomedical metabolomics studies -- 2.2.1. Blood collection tubes are potential sources of chemical noise disturbing metabolomics analysis -- 2.2.2. Additives in plasma blood collection tubes which can be used and which should be avoided -- 2.2.3. Additives in serum blood collection tubes may lead to chemical noise 2.2.4. Dried blood spot metabolomics: Stability of the detected mixture of metabolites from erythrocytes, leukocytes, thr ... -- 2.2.5. Urine cups and containers: Pretests are imperative to avoid analytical problems -- 2.3. Animal studies: Some pre-analytical characteristics are different from human biomedical metabolomics -- 3. Collection, handling, and storage of body fluids for metabolomics investigations -- 3.1. Blood -- 3.1.1. Handling of whole blood can greatly affect the sample quality and the metabolome of plasma and serum -- Plasma: Time and temperature until plasma separation is crucial. - Serum: The coagulation process must be tightly controlled |
Beschreibung: | 1 Online-Ressource (268 Seiten) |
ISBN: | 0128127856 9780128127858 |
Internformat
MARC
LEADER | 00000nmm a2200000zc 4500 | ||
---|---|---|---|
001 | BV047050402 | ||
003 | DE-604 | ||
005 | 20211209 | ||
007 | cr|uuu---uuuuu | ||
008 | 201207s2020 |||| o||u| ||||||eng d | ||
020 | |a 0128127856 |9 0-12-812785-6 | ||
020 | |a 9780128127858 |9 978-0-12-812785-8 | ||
035 | |a (ZDB-4-NLEBK)2267191 | ||
035 | |a (OCoLC)1226698072 | ||
035 | |a (DE-599)BVBBV047050402 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
049 | |a DE-91 | ||
082 | 0 | |a 572/.4 | |
245 | 1 | 0 | |a Metabolomics for biomedical research |c edited by Jerzy Adamski |
264 | 1 | |a London, United Kingdom ; San Diego, CA, United States ; Cambridge, MA, United States ; Kidlington, Oxford, United Kingdom |b Academic Press, an imprint of Elsevier |c 2020 | |
300 | |a 1 Online-Ressource (268 Seiten) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
500 | |a Intro -- Metabolomics for Biomedical Research -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Introduction to metabolomics -- 1. What is metabolomics? -- 2. Flow chart of metabolomic research -- 2.1. Scientific question -- 2.2. Study design: General aspects -- 2.3. Study design: Pilot study and power calculation -- 2.4. Study design: Sample identity -- 2.5. Study design: Preanalytics -- 2.6. Study design: Sample matrix -- 2.7. Study design: Confounders -- 2.8. Study design: Time schedule -- 2.9. Study design: Randomization -- 2.10. Study design: Budgeting and resources | ||
500 | |a 2.11. Study design: Contingency plan -- 2.12. Study design: Legal aspects -- 2.13. Study design: Governance -- 2.14. Study design: Replication -- 2.15. Analytics -- 2.16. Data validation -- 2.17. Data release -- 3. Future trends -- 3.1. Standardization -- 3.2. Coverage and speed -- 3.3. Accessibility -- 3.4. Mechanisms of disease -- 3.5. Biomarkers -- Acknowledgments -- References -- Chapter 2: Confounders in metabolomics -- 1. Introduction to the confounder concept -- 2. Important confounders in metabolomics -- 2.1. Genetic background and ethnicity -- 2.2. Sex -- 2.3. Age -- 2.4. Nutrition | ||
500 | |a 3. Body mass index -- 3.1. Physical activity -- 3.2. Alcohol -- 3.3. Smoking -- 3.4. Stress -- 3.5. Circadian rhythm -- 3.6. Hormonal status -- 3.7. Medication -- 3.8. Lifestyle -- 4. Disease -- 5. Consequences for study design -- 6. Future trends -- References -- Chapter 3: Pre-analytics in biomedical metabolomics -- 1. Introduction -- 2. Principles to be considered before the collection of body fluids for biomedical metabolomics -- 2.1. Patients instructions and sophisticated questionaries can avoid outliers -- Points to be considered before sample collection | ||
500 | |a Suggestions of choice for additional points in a study questionnaire -- 2.1.1. Control groups: Undiagnosed, asymptomatic diseases of apparently healthy subjects can bias metabolomics findings -- 2.2. Sample collectors for blood and urine in biomedical metabolomics studies -- 2.2.1. Blood collection tubes are potential sources of chemical noise disturbing metabolomics analysis -- 2.2.2. Additives in plasma blood collection tubes which can be used and which should be avoided -- 2.2.3. Additives in serum blood collection tubes may lead to chemical noise | ||
500 | |a 2.2.4. Dried blood spot metabolomics: Stability of the detected mixture of metabolites from erythrocytes, leukocytes, thr ... -- 2.2.5. Urine cups and containers: Pretests are imperative to avoid analytical problems -- 2.3. Animal studies: Some pre-analytical characteristics are different from human biomedical metabolomics -- 3. Collection, handling, and storage of body fluids for metabolomics investigations -- 3.1. Blood -- 3.1.1. Handling of whole blood can greatly affect the sample quality and the metabolome of plasma and serum -- Plasma: Time and temperature until plasma separation is crucial. - Serum: The coagulation process must be tightly controlled | ||
650 | 4 | |a Metabolites | |
700 | 1 | |a Adamski, Jerzy |d ca. 20./21. Jh. |0 (DE-588)1247186709 |4 edt | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 978-0-12-812784-1 |
912 | |a ZDB-4-NLEBK | ||
999 | |a oai:aleph.bib-bvb.de:BVB01-032457782 | ||
966 | e | |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=2267191 |l TUM01 |p ZDB-4-NLEBK |q TUM_PDA_EBSCOMED_Kauf |x Aggregator |3 Volltext |
Datensatz im Suchindex
_version_ | 1804182037784952832 |
---|---|
adam_txt | |
any_adam_object | |
any_adam_object_boolean | |
author2 | Adamski, Jerzy ca. 20./21. Jh |
author2_role | edt |
author2_variant | j a ja |
author_GND | (DE-588)1247186709 |
author_facet | Adamski, Jerzy ca. 20./21. Jh |
building | Verbundindex |
bvnumber | BV047050402 |
collection | ZDB-4-NLEBK |
ctrlnum | (ZDB-4-NLEBK)2267191 (OCoLC)1226698072 (DE-599)BVBBV047050402 |
dewey-full | 572/.4 |
dewey-hundreds | 500 - Natural sciences and mathematics |
dewey-ones | 572 - Biochemistry |
dewey-raw | 572/.4 |
dewey-search | 572/.4 |
dewey-sort | 3572 14 |
dewey-tens | 570 - Biology |
discipline | Biologie |
discipline_str_mv | Biologie |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04364nmm a2200397zc 4500</leader><controlfield tag="001">BV047050402</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20211209 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">201207s2020 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0128127856</subfield><subfield code="9">0-12-812785-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780128127858</subfield><subfield code="9">978-0-12-812785-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-NLEBK)2267191</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1226698072</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047050402</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">572/.4</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Metabolomics for biomedical research</subfield><subfield code="c">edited by Jerzy Adamski</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London, United Kingdom ; San Diego, CA, United States ; Cambridge, MA, United States ; Kidlington, Oxford, United Kingdom</subfield><subfield code="b">Academic Press, an imprint of Elsevier</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (268 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Intro -- Metabolomics for Biomedical Research -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Introduction to metabolomics -- 1. What is metabolomics? -- 2. Flow chart of metabolomic research -- 2.1. Scientific question -- 2.2. Study design: General aspects -- 2.3. Study design: Pilot study and power calculation -- 2.4. Study design: Sample identity -- 2.5. Study design: Preanalytics -- 2.6. Study design: Sample matrix -- 2.7. Study design: Confounders -- 2.8. Study design: Time schedule -- 2.9. Study design: Randomization -- 2.10. Study design: Budgeting and resources</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">2.11. Study design: Contingency plan -- 2.12. Study design: Legal aspects -- 2.13. Study design: Governance -- 2.14. Study design: Replication -- 2.15. Analytics -- 2.16. Data validation -- 2.17. Data release -- 3. Future trends -- 3.1. Standardization -- 3.2. Coverage and speed -- 3.3. Accessibility -- 3.4. Mechanisms of disease -- 3.5. Biomarkers -- Acknowledgments -- References -- Chapter 2: Confounders in metabolomics -- 1. Introduction to the confounder concept -- 2. Important confounders in metabolomics -- 2.1. Genetic background and ethnicity -- 2.2. Sex -- 2.3. Age -- 2.4. Nutrition</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">3. Body mass index -- 3.1. Physical activity -- 3.2. Alcohol -- 3.3. Smoking -- 3.4. Stress -- 3.5. Circadian rhythm -- 3.6. Hormonal status -- 3.7. Medication -- 3.8. Lifestyle -- 4. Disease -- 5. Consequences for study design -- 6. Future trends -- References -- Chapter 3: Pre-analytics in biomedical metabolomics -- 1. Introduction -- 2. Principles to be considered before the collection of body fluids for biomedical metabolomics -- 2.1. Patients instructions and sophisticated questionaries can avoid outliers -- Points to be considered before sample collection</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Suggestions of choice for additional points in a study questionnaire -- 2.1.1. Control groups: Undiagnosed, asymptomatic diseases of apparently healthy subjects can bias metabolomics findings -- 2.2. Sample collectors for blood and urine in biomedical metabolomics studies -- 2.2.1. Blood collection tubes are potential sources of chemical noise disturbing metabolomics analysis -- 2.2.2. Additives in plasma blood collection tubes which can be used and which should be avoided -- 2.2.3. Additives in serum blood collection tubes may lead to chemical noise</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">2.2.4. Dried blood spot metabolomics: Stability of the detected mixture of metabolites from erythrocytes, leukocytes, thr ... -- 2.2.5. Urine cups and containers: Pretests are imperative to avoid analytical problems -- 2.3. Animal studies: Some pre-analytical characteristics are different from human biomedical metabolomics -- 3. Collection, handling, and storage of body fluids for metabolomics investigations -- 3.1. Blood -- 3.1.1. Handling of whole blood can greatly affect the sample quality and the metabolome of plasma and serum -- Plasma: Time and temperature until plasma separation is crucial. - Serum: The coagulation process must be tightly controlled</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metabolites</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Adamski, Jerzy</subfield><subfield code="d">ca. 20./21. Jh.</subfield><subfield code="0">(DE-588)1247186709</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">978-0-12-812784-1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-032457782</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=2267191</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-4-NLEBK</subfield><subfield code="q">TUM_PDA_EBSCOMED_Kauf</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
id | DE-604.BV047050402 |
illustrated | Not Illustrated |
index_date | 2024-07-03T16:07:47Z |
indexdate | 2024-07-10T09:01:11Z |
institution | BVB |
isbn | 0128127856 9780128127858 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-032457782 |
oclc_num | 1226698072 |
open_access_boolean | |
owner | DE-91 DE-BY-TUM |
owner_facet | DE-91 DE-BY-TUM |
physical | 1 Online-Ressource (268 Seiten) |
psigel | ZDB-4-NLEBK ZDB-4-NLEBK TUM_PDA_EBSCOMED_Kauf |
publishDate | 2020 |
publishDateSearch | 2020 |
publishDateSort | 2020 |
publisher | Academic Press, an imprint of Elsevier |
record_format | marc |
spelling | Metabolomics for biomedical research edited by Jerzy Adamski London, United Kingdom ; San Diego, CA, United States ; Cambridge, MA, United States ; Kidlington, Oxford, United Kingdom Academic Press, an imprint of Elsevier 2020 1 Online-Ressource (268 Seiten) txt rdacontent c rdamedia cr rdacarrier Intro -- Metabolomics for Biomedical Research -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Introduction to metabolomics -- 1. What is metabolomics? -- 2. Flow chart of metabolomic research -- 2.1. Scientific question -- 2.2. Study design: General aspects -- 2.3. Study design: Pilot study and power calculation -- 2.4. Study design: Sample identity -- 2.5. Study design: Preanalytics -- 2.6. Study design: Sample matrix -- 2.7. Study design: Confounders -- 2.8. Study design: Time schedule -- 2.9. Study design: Randomization -- 2.10. Study design: Budgeting and resources 2.11. Study design: Contingency plan -- 2.12. Study design: Legal aspects -- 2.13. Study design: Governance -- 2.14. Study design: Replication -- 2.15. Analytics -- 2.16. Data validation -- 2.17. Data release -- 3. Future trends -- 3.1. Standardization -- 3.2. Coverage and speed -- 3.3. Accessibility -- 3.4. Mechanisms of disease -- 3.5. Biomarkers -- Acknowledgments -- References -- Chapter 2: Confounders in metabolomics -- 1. Introduction to the confounder concept -- 2. Important confounders in metabolomics -- 2.1. Genetic background and ethnicity -- 2.2. Sex -- 2.3. Age -- 2.4. Nutrition 3. Body mass index -- 3.1. Physical activity -- 3.2. Alcohol -- 3.3. Smoking -- 3.4. Stress -- 3.5. Circadian rhythm -- 3.6. Hormonal status -- 3.7. Medication -- 3.8. Lifestyle -- 4. Disease -- 5. Consequences for study design -- 6. Future trends -- References -- Chapter 3: Pre-analytics in biomedical metabolomics -- 1. Introduction -- 2. Principles to be considered before the collection of body fluids for biomedical metabolomics -- 2.1. Patients instructions and sophisticated questionaries can avoid outliers -- Points to be considered before sample collection Suggestions of choice for additional points in a study questionnaire -- 2.1.1. Control groups: Undiagnosed, asymptomatic diseases of apparently healthy subjects can bias metabolomics findings -- 2.2. Sample collectors for blood and urine in biomedical metabolomics studies -- 2.2.1. Blood collection tubes are potential sources of chemical noise disturbing metabolomics analysis -- 2.2.2. Additives in plasma blood collection tubes which can be used and which should be avoided -- 2.2.3. Additives in serum blood collection tubes may lead to chemical noise 2.2.4. Dried blood spot metabolomics: Stability of the detected mixture of metabolites from erythrocytes, leukocytes, thr ... -- 2.2.5. Urine cups and containers: Pretests are imperative to avoid analytical problems -- 2.3. Animal studies: Some pre-analytical characteristics are different from human biomedical metabolomics -- 3. Collection, handling, and storage of body fluids for metabolomics investigations -- 3.1. Blood -- 3.1.1. Handling of whole blood can greatly affect the sample quality and the metabolome of plasma and serum -- Plasma: Time and temperature until plasma separation is crucial. - Serum: The coagulation process must be tightly controlled Metabolites Adamski, Jerzy ca. 20./21. Jh. (DE-588)1247186709 edt Erscheint auch als Druck-Ausgabe 978-0-12-812784-1 |
spellingShingle | Metabolomics for biomedical research Metabolites |
title | Metabolomics for biomedical research |
title_auth | Metabolomics for biomedical research |
title_exact_search | Metabolomics for biomedical research |
title_exact_search_txtP | Metabolomics for biomedical research |
title_full | Metabolomics for biomedical research edited by Jerzy Adamski |
title_fullStr | Metabolomics for biomedical research edited by Jerzy Adamski |
title_full_unstemmed | Metabolomics for biomedical research edited by Jerzy Adamski |
title_short | Metabolomics for biomedical research |
title_sort | metabolomics for biomedical research |
topic | Metabolites |
topic_facet | Metabolites |
work_keys_str_mv | AT adamskijerzy metabolomicsforbiomedicalresearch |